[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Toronto\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":689},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,41,0,25,[9,48,74,107,136,166,198,223,248,278,310,335,363,392,417,444,474,498,519,542,566,592,615,639,665],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100525222","time-restricted-eating-window-timing-type-2-diabetes-status-and-sex-on-glycemic-control-100525222",false,"NCT06118931","Time-restricted Eating, Window Timing, Type 2 Diabetes Status and Sex on Glycemic Control","The Impact of Time-restricted Eating, Window Timing, Type 2 Diabetes Status and Sex on Glycemic Control","Inclusion Criteria:\n\n* Aged 40 years or older\n* Body mass index \\\u003C50 kg\u002Fm2\n* Have access to an Apple or Android cellphone with Bluetooth.\n* Have type 2 diabetes or be at risk for type 2 diabetes (defined as self-report of pre-diabetes, a recent (within 12 months) measure of HbA1c between 5.7 and 6.4%, waist circumference (WC) that is BMI specific; for women: BMI \\>= 18.5-24.9, WC \\>= 80cm; BMI \\>= 25-29.9, WC \\>= 90cm; BMI \\>= 30-34.9, WC \\>= 105cm; BMI \\>= 35+, WC \\>= 115cm; for men: BMI \\>= 18.5-24.9, WC \\>= 90cm; BMI \\>= 25-29.9, WC \\>= 100cm; BMI \\>= 30-34.9, WC \\>= 110cm; BMI \\>= 35+, WC \\>= 125cm.\n\nExclusion Criteria:\n\n* Individuals with type 2 diabetes will be excluded if: (1) currently on \\>2 monotherapies for diabetes, (2) have had diabetes therapy medication or dosage changes \\\u003C3 months, (3) self-reported hemoglobin A1c \\>9.0%, (4) taking exogenous insulin, or (5) taking sulfonylureas\n* The following exclusion criteria applies to all potential participants:\n\n  1. History of or referral for bariatric surgery\n  2. Weight loss \\>3% in the last 3 months\n  3. Taking antiobesity (weight loss) medications\n  4. Body weight \\>390lbs\n  5. Diagnosed with severe cognitive disorder that precludes them from giving consent\n  6. Inability or unwillingness to change their eating window to follow those prescribed in the study\n  7. Currently consistently eating during \\\u003C11.5 hour period .\n  8. Physician-diagnosed eating disorder\n  9. Having a pacemaker or receiving dialysis.\n  10. Not having access to a Lifelabs location.","ALL","40 Years",{"count":20,"type":21},123,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study will evaluate the effectiveness of time-restricted eating (TRE), which is a form of intermittent fasting. When performing TRE, individuals consume all of their calories within a specific time window and then only consume water or other no calorie drinks the rest of the day. TRE is performed each day. There is no restriction on the quality or amount of food that people can consume during their eating window (ad libitum eating) with TRE, which can last anywhere from 4 to 12 hours. We are comparing three different 9-hour eating windows to determine whether the start and stop time of the eating window impact blood sugar control in individuals with obesity who also have or are at risk for type 2 diabetes. We also aim to determine if there are differences in the effects of the timing of eating window between males and females.",[27,28,29,30],"Diabetes Mellitus, Type 2","Obesity","Prediabetic State","Hyperglycemia",[32,33,28,34],"Time-restricted eating","Type 2 Diabetes","Glycemic Control","RECRUITING","2026-06-26",{"date":38,"type":39},"2026-06-30","ACTUAL",{"date":41,"type":39},"2025-06-28",{"date":43,"type":21},"2027-06-28",{"name":45,"class":46},"University of Toronto","OTHER",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":47},"100645289","migration-rate-for-continuous-adductor-canal-block-catheters-after-primary-total-knee-arthroplasty-surgery-a-comparison-between-two-insertion-techniques-100645289","NCT07681622","Migration Rate for Continuous Adductor Canal Block Catheters After Primary Total Knee Arthroplasty Surgery: a Comparison Between Two Insertion Techniques","Migration Rate for Continuous Adductor Canal Block Catheters After Primary Total Knee Arthroplasty Surgery: a Comparison Between the Interfascial Plane Between SArtorious Muscle and FEmoral Artery (ISAFE) and the Out Of Plane Parallel to Saphenous Nerve (OOPS) Techniques: The ISAFE x OOPS Trial","ISAFExOOPS","Inclusion Criteria:\n\n* Non-pregnant patients older than 18 years of age;\n* Patients undergoing unilateral primary total knee arthroplasty in an inpatient regime;\n* American Society of Anesthesiologist (ASA) physical status Class I - IV patients;\n* With sufficient understanding and co-operation about usage of a perineural catheter for pain management;\n* With body mass index (BMI) under 45;\n* With no history of strong opioid use of more than 30 mg of oral morphine equivalent (OME)\u002Fday during the 2 weeks preceding the surgery;\n* No alcohol or drug use disorder history;\n* With no contra-indication for the performance of ACB and IPACK block;\n* With no contra-indication for spinal anesthesia;\n* With no contra-indication for CACB catheter insertion (local site infection, systemic infection, anatomical abnormality);\n* With no contra-indication for the medications to be used accordingly with the study protocol (ropivacaine, lidocaine, mepivacaine, midazolam, fentanyl, propofol, cefazolin, tranexamic acid, dexamethasone, ondansetron, celecoxib, acetaminophen, hydromorphone);\n* Speak and understand the English language;\n* Agree to participate on this study through the signature of the consent form.\n\nExclusion Criteria:\n\n* They have a failed spinal anesthesia and needs for a conversion to general anesthesia;\n* The peripheral nerve blocks are not possible to be performed due to technical difficulties;\n* A deviation of the protocol occurs (not follow the standardized postoperative analgesia orders; need an emergency re-operation of the same knee, in less than 24 hours, due to a surgical complication; have an important perioperative complication, leading to abnormal level of conscience);\n* CACB catheter has issues on its function and needs to be removed before the migration assessment\n* Patient decides to withdraw from the study.",true,"21 Years",{"count":59,"type":21},48,[24],"Continuous adductor canal block (CACB) is becoming increasingly popular for providing postoperative analgesia following knee arthroplasties. These continuous blocks are provided through inserted nerve catheters and effectively extend the duration of analgesia, thereby reducing opioid consumption. This, in turn, helps minimize opioid-related side effects, promotes early ambulation, and supports earlier discharge. However, catheter migration remains a significant concern, as the catheter tip can become displaced from the adductor canal due to movements associated with ambulation or physiotherapy. In this study, the investigators compare the migration rates of two different techniques for CACB catheters insertion: the Interfascial plane between SArtorious muscle and FEmoral artery (ISAFE) and the Out Of Plane parallel to Saphenous nerve (OOPS) techniques. Pain scores and opioid consumption on postoperative day 1 (POD1) will also be assessed as secondary outcomes. The hypothesis is that both techniques will result in similar migration rates of CACB catheter.",[63,64],"Arthroplasty Replacement, Knee","Anesthesia Conduction","NOT_YET_RECRUITING","2026-06-25",{"date":68,"type":39},"2026-07-02",{"date":70,"type":21},"2026-06",{"date":72,"type":21},"2027-06",{"name":45,"class":46},{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":56,"sex":17,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":91,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},"100528138","using-neuroimaging-and-behavioral-assessments-to-understand-late-talking-100528138","NCT06156865","Using Neuroimaging and Behavioral Assessments to Understand Late Talking","Neuroimaging Reveals Treatment-related Changes in DLD: A Randomized Controlled Trial (Supplement)","Inclusion Criteria:\n\n* child and parent are monolingual\u002Fnative (primarily) English speakers\n* child is enrolled at one of the participating facilities\n* child is recruited via word of mouth, including social media\n* child is between 18 and 30 months of age\n* child does not have any contraindications to magnetic resonance imaging (i.e., intracranial metal implants, claustrophobia)\n* child does not have any uncorrected vision challenges\n\nExclusion Criteria:\n\n* Child does not meet criteria for LT or typical development\n* Standard magnetic resonance imaging exclusion criteria\n* Gestational age less than 37 weeks or greater than 42 weeks\n* Special education placement of child based on ability or behavior","18 Months","30 Months",{"count":84,"type":21},45,[24],"Late talkers (LT), representing 10-20% of children under 3, demonstrate hallmark syntax and vocabulary deficits similar to preschoolers with developmental language disorder. While effective and early interventions can mitigate the impact of late talking, not enough is known about its neural basis, yet is needed to inform the design of more individualized interventions. This proposed effort uses neuroimaging, along with behavioral methods, with the goal of better understanding the memory-language mechanisms that underlie learning and late talking, while also considering their association to treatment-related changes in LT.",[88,89,90],"Developmental Language Disorder","Language Delay","Language Development",[92,93,94,95,96,97],"children","late talking","typical development","assessment","intervention","neuroimaging","2026-05-29",{"date":100,"type":39},"2026-06-02",{"date":102,"type":39},"2024-01-19",{"date":104,"type":21},"2027-06-30",{"name":45,"class":46},2,{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":17,"minAge":114,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":132,"leadSponsor":134,"locationsCount":135},"100562513","stroke-motor-recovery-for-the-hand-and-fingers-100562513","NCT06604143","Stroke Motor Recovery for the Hand and Fingers","Discovering the Potential for Motor Recovery in People Living With Stroke","Inclusion Criteria:\n\n* Over 18 years of age\n* Diagnosis of first time unilateral ischemic or hemorrhagic\n* Stroke occurrence: \\> 6 months and \\\u003C 2 years\n* Able to perform active finger movements (Chedoke-McMaster (CM) Impairment Inventory of the Hand, Stage ≥ 3)\n\nExclusion Criteria:\n\n* History of developmental, neurological, or major psychiatric disorders\n* Cognitive deficits (\\\u003C 23\u002F30 Montreal Cognitive Assessment)\n* Apraxia (\\\u003C2SD mean Waterloo Apraxia test)\n* Neglect (\\> 40\u002F100, Sunnybrook Neglect Assessment Procedure)\n* Cerebellar stroke\n* Musculoskeletal injury affecting motor performance\n* Inability to sit in a chair and perform exercises for sustained periods\n* Contraindications to MRI","19 Years","80 Years",{"count":117,"type":21},40,[24],"The goal of this clinical trial is to compare two rehabilitation methods to improve finger movements in people who have had a stroke. The main question it aims to answer is which of these two training methods leads to the most improvement:\n\n1. Teaching people to reach their movement goals using any strategies they like.\n2. Teaching people to improve their movement technique and avoid compensatory strategies.\n\nThere is no one-size-fits-all approach. The second goal is to find out who might benefit more from each method. Some people with stroke may rely on compensatory strategies due to severe impairment, while others with milder strokes might benefit more from techniques that enhance movement quality.\n\nThe third goal is to take pictures of the brain to see how it changes with each method. This will help researchers understand how the brain adapts after a stroke and could lead to treatments that target the brain directly.\n\nParticipants will:\n\n1. Visit the lab for clinical and research assessments on weeks 1, 4, 5, and 15.\n2. Complete 10 days of piano training.\n3. Undergo magnetic resonance imaging (MRI) scans twice, once in week 1 and once in week 4.",[121],"Stroke",[123,124,125,126,127],"Motor system","Stroke rehabilitation","Magnetic resonance imaging","Kinematics","Music","2026-05-07",{"date":130,"type":39},"2026-05-08",{"date":128,"type":39},{"date":133,"type":21},"2027-12-31",{"name":45,"class":46},5,{"id":137,"slug":138,"hasResults":12,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":12,"sex":17,"minAge":143,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":22,"phases":146,"briefSummary":147,"conditions":148,"keywords":150,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":47},"100636729","reflect-a-novel-group-based-compassion-focussed-cognitive-behavioural-approach-to-core-beliefs-in-psychosis-100636729","NCT07569471","REFLECT: A Novel Group-Based Compassion-Focussed Cognitive Behavioural Approach to Core Beliefs in Psychosis","REFLECT","Inclusion Criteria:\n\n1. Above the age of 18.\n2. Diagnosis of SSD (i.e., Schizophrenia, Schizophreniform, Schizoaffective Disorder, or Delusional Disorder), confirmed based on self-report.\n3. Have current symptoms related to psychosis (as determined by a score of 2 or higher on the SAPS).\n4. Engaged in current outpatient treatment for psychosis (e.g., medication management by psychiatrist or general practitioner, case management, community mental health treatment, etc.).\n5. Has or has access to personal technology (e.g., smartphone, tablet, or laptop\u002Fcomputer) with access to wifi or cellular data.\n\nExclusion Criteria:\n\n1. Not capable of providing informed consent (see Consent Procedures).\n2. Does not have an SSD diagnosis.\n3. Does not experience current delusions.\n4. Not currently involved in outpatient treatment.\n5. Is currently receiving CBTp.\n6. Does not own or have access to personal technology (e.g., smartphone, tablet, or laptop\u002Fcomputer) with access to wifi or cellular data.","18 Years",{"count":145,"type":21},38,[24],"The current study is an open-label, proof-of-concept, pilot trial examining the feasibility, safety, and preliminary efficacy of a 6-week group therapy intervention targeting core beliefs related to symptoms of psychosis. Core beliefs are theorized to be central to the development and maintenance of psychosis and other mental health conditions; however, research on how to address this key mechanism in psychosis is rarely directly studied.\n\nThe primary questions it aims to answer include:\n\n1. Is targeting core beliefs in a technology-supported remote group therapy format safe and feasible?\n2. Does targeting core beliefs result in measurable change in core beliefs?\n\nThe investigators hypothesize that this intervention will be safe and feasible, and that we will see improvements in maladaptive core beliefs.\n\nSecondary outcomes include changes in positive and negative symptoms, personal recovery, and whether there are improvements in other cognitive mechanisms, like cognitive biases, and behavioural mechanisms, like safety behaviours.\n\nAs this is an open pilot trial, there is no comparison group. All participants will have the opportunity to participate in the group therapy intervention.\n\nParticipants will be asked to take part in four assessment visits: screening (Day 1), baseline (pre-intervention; Day 1-14), post-intervention (Weeks 7-9), and a three-month follow-up (Weeks 19-21). The intervention under investigation is a 6-week group therapy intervention consisting of weekly 2-hour sessions delivered via video conferencing, with weekly home practice assignments delivered and completed remotely.",[149],"Schizophrenia Spectrum & Other Psychotic Disorders",[151,152,153,154,155,156,157],"Psychosis","Cognitive Behavioural Therapy","Group Therapy","Remote Therapy","Online Therapy","Schizophrenia","Schizoaffective Disorder","2026-04-28",{"date":160,"type":39},"2026-05-06",{"date":162,"type":39},"2026-03-31",{"date":164,"type":21},"2028-01-30",{"name":45,"class":46},{"id":167,"slug":168,"hasResults":12,"nctId":169,"briefTitle":170,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":12,"sex":17,"minAge":143,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":22,"phases":175,"briefSummary":176,"conditions":177,"keywords":184,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":47},"100585860","the-switch-substitution-of-high-with-low-ultra-processed-soy-protein-foods-in-a-guideline-based-diet-intervention-for-cardiometabolic-health-trial-100585860","NCT06907862","The SWITCH (Substitution of High With Low Ultra-processed Soy Protein Foods In a Guideline-based Diet inTervention for Cardiometabolic Health) Trial","SWITCH","Inclusion Criteria:\n\n* Obesity (BMI and waist circumference using sex and ethnic-specific thresholds for obesity and significant abdominal adiposity)\n* adults (≥18years)\n* hypertension (SBP 120-160 mmHg)\n* on stable antihypertensive, antihyperglycemic, antihyperlipidemic, or anti-obesity medications (≥3-months)\n* not planning new weight loss for the duration of the trial\n* 50% living with type 2 diabetes, HbA1c 6.5-9.0%\n\nExclusion Criteria:\n\n* Individuals with a history of major cardiovascular events in the last year (stroke or myocardial infarction)\n* type 1 diabetes diagnosis\n* recent weight loss or weight gain (≥5% over \\\u003C6 months)\n* current treatment with insulin\n* eating disorders; substance abuse disorders\n* serious depression or psychiatric disorders\n* bariatric or recent surgery (\\\u003C6 months)\n* uncontrolled hypertension (SBP\u002FDBP \\>160\u002F100 mmHg)\n* angina pectoris\n* gastrointestinal and malabsorption disorders (i.e. inflammatory bowel disease, celiac), pancreatitis, chronic kidney or liver disease, cardiac condition that compromises normal function (e.g. mitral valve disease, heart failure), major disability or disorder requiring continuous medical attention.\n* herb or supplement use that may affect primary outcome.\n* alcohol use \\>3 drinks\u002Fday; participation in another trial.\n* allergies\u002Fintolerances to soy; allergies\u002Fintolerances to tree nuts, peanuts and seeds (the combination of all 3).\n* chronic or prescribed use of certain medications including prescription high dose NSAIDs, antacids, warfarin, medications affecting NO synthesis (i.e. sildenafil, organic nitrates, etc.)\n* acute or chronic infection (e.g. active HIV, TB, COVID-19, chronic inflammatory infections)\n* chronic inflammatory condition (such as rheumatoid arthritis)\n* use of antibiotics within 3-months of the study start",{"count":174,"type":21},300,[24],"This is a randomized, controlled, parallel study with 3 experimental arms aimed to assess the effect of a digital dietary intervention (web-based app, online behavior change curriculum) enhanced with 10 servings of vegetables and fruit (5 as dietary advice within the app, 5 within a dehydrated vegetable and fruit blend), with or without high Ultra Processed Food (UPF) soy-containing proteins compared to standard of care (usual care) on systolic blood pressure (SBP; primary outcome), and other key cardiometabolic endpoints over 12-weeks in adults living with hypertension and obesity, 50% with type 2 diabetes. The main questions this study aims to answer are:\n\n1. Are nutrient-dense, high-UPF soy-protein foods similar (non-inferior) to low-UPF soy-protein foods in the context of a guidelines-based diet in their effect on blood pressure and other cardiometabolic risk factors?\n2. Does an enhanced digital dietary intervention lead to meaningful reductions in blood pressure and other cardiometabolic risk factors compared to standard of care?\n\nParticipants who are eligible and consent to be part of this study will be randomized to one of the following groups: 1) Active treatment (high-UPF soy-containing enhanced digital dietary intervention), 2) Reference treatment (low-UPF soy-containing enhanced digital dietary intervention), or 3) Control (standard of care).\n\nParticipant Requirements:\n\nDuring the 12-week intervention, all participants will be required to attend in-person clinic visits at baseline (week 0), week 8 and 12.\n\nBaseline Visit (Week 0): Participants will be asked to arrive in a fasted state (no food or beverages, except water, for 10-12 hours before the visit).\n\n* Undergo various assessments, including anthropometric measurements, office blood pressure readings, and blood sampling (via a capillary finger prick and blood sample taken by the study nurse).\n* Review the 7-day food records completed using the Keenoa mobile app one week prior to clinic visit.\n* Bring fecal and urine samples from home.\n* Complete and review all questionnaires received via email one week prior.\n\nTelephone Check-in (Week 1):\n\nOne week after beginning the study, the study staff will call participants to check in on how participants are following the protocol and answer any questions.\n\nMid-Study Visit (Week 8): Participants will be asked to arrive in a fasted state (no food or beverages, except water, for 10-12 hours before the visit).\n\n* Have their office blood pressure and anthropometric measurements taken.\n* Complete and review all questionnaires received via email one week prior\n* Review the 3-day food records completed using the Keenoa mobile app one week prior to clinic visit.\n\nFinal Study Visit (Week 12): Participants will be asked to arrive in a fasted state (no food or beverages, except water, for 10-12 hours before the visit).\n\n* Undergo various assessments, including anthropometric measurements, office blood pressure readings, and blood sampling (via a capillary finger prick and blood sample taken by the study nurse).\n* Review the 7-day food records completed using the Keenoa mobile app one week prior to clinic visit.\n* Bring fecal and urine samples from home.\n* Complete and review all questionnaires received via email one week prior.\n\nThroughout the study, participants will be asked to continue their usual lifestyle and physical activity.\n\nAdditional Requirements for Treatment Groups:\n\nParticipants randomized to the active and reference treatment groups will also be required to:\n\n* Incorporate a study vegetable and fruit blend (provided) into their daily diet for the full 12 weeks\n* Consume soy products categorized as either high ultra processed soy foods at least 4 servings per day, including at least 2 servings of ultra processed soy milk and 2 servings of other soy-based products (e.g., soy yogurt, soy burgers, or soy ground round) or non-ultra processed soy foods at least 4 servings per day, including at least 2 servings of minimally processed soy milk, 1 serving of edamame or roasted soy nuts, and 1 serving of tofu or tempeh\n* Participate in the digital dietary intervention, which includes: a health app, 7-day Kickstart Package, weekly text message support, and a 7-session online interactive program designed based on behaviour change theory\n* Attend a virtual focus group at Week 4 and complete an online feedback questionnaire",[178,179,180,181,182,183],"Hypertension in Type 2 Diabetes","Diabetes Mellitus Type 2","Dyslipidemia","Hypertension","Metabolic Health","Cardiovascular Risk Factors",[185,181,186,187,188,189],"Randomized controlled trial","Cardiometabolic health","Ultra processed food","technology-based dietary intervention","dehydrated vegetable and fruit blend","2026-04-27",{"date":192,"type":39},"2026-05-04",{"date":194,"type":39},"2025-08-06",{"date":196,"type":21},"2028-06-30",{"name":45,"class":46},{"id":199,"slug":200,"hasResults":12,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":12,"sex":205,"minAge":143,"maxAge":206,"enrollmentInfo":207,"targetDuration":4,"studyType":22,"phases":209,"briefSummary":210,"conditions":211,"keywords":213,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":47},"100573302","influence-of-menstrual-cycle-phase-on-adaptations-to-sprint-interval-training-100573302","NCT06744517","Influence of Menstrual Cycle Phase on Adaptations to Sprint Interval Training","Influence of Menstrual Cycle Phase on Metabolic and Performance Adaptations to Sprint Interval Training","Inclusion Criteria:\n\n* Participating in 150 min of moderate-vigorous physical activity\u002Fweek\n* VO2peak of 'good' or above based on American College of Sport Medicine (ACSM) normative values(greater than 35.0ml\u002Fkg\u002Fmin)\n* Body mass index (BMI) between 18-27 kg\u002Fm2\n* Performing 2-4 structured exercise sessions\u002Fweek.\n* Weight stable (within ± 2kg for at least 6 months)\n* Non-smoker\n* Menstrual cycle length of 27-35 days\n* Minimal menstrual cycle length variability (less than 3 days)\n* Ovulating monthly evidenced by a positive urinary luteinizing hormone surge\n* Blood progesterone concentration greater than 16 nmol\u002FL.\n\nExclusion Criteria:\n\n* Hormonal contraceptive use within the last 3 months\n* Polycystic ovarian syndrome (PCOS) or endometriosis\n* Failure to meet MC verification criteria.\n* Diagnosed with cardiovascular or metabolic disease, hyper- or hypogonadism, and\u002For PCOS\n* The use of medication for managing blood glucose or lipid metabolism\n* Current use of oral contraceptives or use within the last 3 months\n* Irregular menstrual cycles (\\\u003C27 days or \\>35 days)\n* Pregnant or post-partum in the last 12 months, lactating or breast feeding within 3 months of the start of study, or menopausal\n* Recreational smoking tobacco\n* Inability to perform the study exercise protocols or follow the pre-trial dietary or physical activity controls\n* Taking medications affecting substrate metabolism (corticosteroids or nSAIDs)\n* Actively engaging in a low-carbohydrate diet (e.g., ketogenic, Atkins)","FEMALE","35 Years",{"count":208,"type":21},24,[24],"Sprint interval training improves endurance performance and induces metabolic adaptations in muscle. Most research demonstrating these responses has been conducted in males, with limited studies evaluating changes to endurance performance and skeletal muscle oxidative capacity in females. Moreover, it is currently unknown if training in specific phases of the menstrual cycle influences adaptations to training. Thus, the purpose of the present study is to compare adaptations to 2 weeks of sprint interval training performed in the follicular vs. luteal phase of the menstrual cycle in healthy, eumenorrheic women.",[212],"Healthy",[214,215],"exercise","women",{"date":217,"type":39},"2026-04-29",{"date":219,"type":39},"2025-01-01",{"date":221,"type":21},"2026-07",{"name":45,"class":46},{"id":224,"slug":225,"hasResults":12,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":12,"sex":17,"minAge":143,"maxAge":231,"enrollmentInfo":232,"targetDuration":4,"studyType":22,"phases":234,"briefSummary":235,"conditions":236,"keywords":238,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":106},"100579384","the-t-cell-activator-of-cell-killing-tack-it-on-study-100579384","NCT06823596","The T Cell Activator of Cell Killing (\"TACK\") IT ON\" STUDY","Short-term Addition of Efavirenz to Induce CARD8-mediated Reduction of Persistent Nonsuppressible HIV Viremia in People With High Adherence to ART.","\"TACKITON","Inclusion criteria for participants are:\n\n* Ability to provide signed written informed consent; age \\>18 years\n* Documented HIV diagnosis\n* Continuous antiretroviral therapy for \\> 4 years with no issues of adherence\n* Taking a stable ART regimen, without the inclusion of a protease inhibitor\n* At least 4 HIV viral loads \\>20 and \\\u003C 400 copies\u002Fml over the past two years\n* No documented resistance to EFV in history, no PI including ritonavir in current ART regimen or during study period\n* No evidence of EFV resistance by plasma virus sequencing at screening visit\n* Non-pregnant throughout the study period, if female sex\n* Good general health as shown by medical history and screening laboratory tests at the screening visit:\n\n  * Hemoglobin ≥ 85 g\u002FL, white blood cell count (WBC) \\> 3,000 cells\u002Fmm3\n  * Total lymphocyte count .750 X109\u002FL\n  * Platelets = 50 to 550 X109\u002FL\n  * Chemistry panel: alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase \\\u003C 5 times the institutional upper limit of normal (ULN);\n* Willing to undergo either leukapheresis or blood draw at visits 2 and 7 (participants will be given the option to undergo blood draws rather than leukapheresis)\n* Ability to add efavirenz to their current ART HIV medication re: avoid drug to drug interactions\n\nExclusion criteria\n\nThere will be no exclusion criteria based on gender\u002Fgender identity, ethnoracial composition, language, socioeconomic status, mode of HIV acquisition or sexual orientation\u002Fidentity. Any participant who requires language interpretation can and will be accommodated for by the participation of translators, either at the patient's choice and\u002For with the assistance of the translator services provided by local ASO organizations. Exclusion criteria for participants include the following:\n\n* Participants who would have difficulty participating in a trial due to non-compliance\n* No active medications \u002F illicit drugs that could adversely affect study compliance\n* Currently prescribed and using EFV as part of ongoing ART treatment regimen for HIV suppression\n* Currently prescribed a protease inhibitor or pharmacologic booster (cobisistat) as part of current ART regimen\n* History of major psychiatric condition that would be adversely affected by efavirenz\n* Diagnosed severe cognitive impairment or of strong concern in the judgement of investigators that efavirenz would adversely affect participant\n* Documented or suspected history of resistance to any NNRTI including efavirenz, nevirapine or rilpivirine\n* History of severe intolerance or documented allergy to efavirenz\n* Participants with any of the following abnormal laboratory results at the screening visit:\n\n  * Hemoglobin \\\u003C 85 g\u002FL\n  * Lymphocyte count \\\u003C .750 X109\u002FL\n  * Platelet count \\\u003C 50 X109\u002FL or \\> 550 X109\u002FL\n  * AST or ALT \\> 5X the upper limit of normal\n  * Creatinine \\> 250 µmol\u002FL\n* Participants with a malignancy or undergoing chemotherapy\n* Participants with other significant underlying disease (non-HIV-1) that might impinge upon disease progression or death\n* Any concurrent condition requiring the continued use of immunoglobulin, antineoplastic agents, glucocorticoids (other than corticosteroid nasal spray for allergic rhinitis; topical or ophthalmic corticosteroids for acute, uncomplicated dermatitis or conjunctivitis; over the counter medications for acute, uncomplicated dermatitis for treatment period not longer than 14 days) or other immunomodulator medications (other than NSAIDS which will be allowed for any length of time)\n* Active drug or alcohol use\u002Fdependence that, in the opinion of the investigator, would interfere with adherence to study requirements\n* Any illness or conditions including acute illnesses that, in the opinion of the investigator, may affect the safety of the participant or the evaluation of any study endpoints\n* Any other conditions judged by the investigator that would limit the evaluation of a participant\n* Any confirmed or suspected immunosuppressive or immunodeficient state (except HIV infection for Group-3), asplenia, recurrent severe infections and chronic use (more than 14 days) immunosuppressant medication within the past six months (topical steroids are allowed)","89 Years",{"count":233,"type":21},26,[24],"Antiretroviral therapy or ART blocks HIV replication reducing plasma viral loads to undetectable levels but has no effect on persistently infected cells in the body, called the virus reservoir. These cells carry infectious HIV capable of restarting HIV replication if therapy is stopped. The reservoir is so stable forcing people to adhere life-long ART. Over 5% of ART adherent individuals continue to have residual non-suppressive viremia (NSV) detected by clinical assays (40-400 copies\u002Fml). Residual viremia reflects a more persistent reservoir and has the potential for increased morbidity. For eg., persistent expression of HIV proteins contributes to inflammation, and can lead to comorbidities. Recently, a novel way to target this reservoir called \"TACK\" or \"Targeted activator of cell killing\" is proposed. TACK compounds only target HIV infected cells and directly kill them by inducing a natural killing program (called the inflammasome). Recently the HIV drug, Efavirenz (EFV), which was used to suppress HIV replication for decades, has now been shown to also be a TACK compound. This pilot study will evaluate the impact of Efavirenz (EFV) in reducing HIV persistence by its ability to be a TACK molecule. So in addition to blocking HIV growth, this compound when added to a current ART regimen can kill HIV infected cells in the test tube. We aim to harness this effect to determine whether the addition of EFV to the current ART regimen in people with NSV can suppress the viremia to undetectable levels by killing those cells. NSV represents the \"the tip of the iceberg\" of those with bigger reservoirs and represents a challenging clinical scenario in dire need of new diagnostic and therapeutic options.\n\nThis pilot study will spark larger clinical trials to advance HIV cure strategies, and will provide new tools to improve the clinical management of people living with HIV.",[237],"Hiv",[239],"Tack it on","2026-03-13",{"date":242,"type":39},"2026-03-17",{"date":244,"type":39},"2025-01-14",{"date":246,"type":21},"2028-11-15",{"name":45,"class":46},{"id":249,"slug":250,"hasResults":12,"nctId":251,"briefTitle":252,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":12,"sex":17,"minAge":254,"maxAge":115,"enrollmentInfo":255,"targetDuration":4,"studyType":22,"phases":257,"briefSummary":258,"conditions":259,"keywords":262,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":106},"100583694","the-effect-of-dairy-intake-on-body-weight-and-composition-and-metabolic-health-in-adolescents-and-seniors-100583694","NCT06879652","The Effect of Dairy Intake on Body Weight and Composition and Metabolic Health in Adolescents and Seniors","Inclusion Criteria (long-term Study):\n\n* Age 15-18 years old (adolescents) or 60-80 years old (seniors)\n* BMI z-score \\>+1SD, \\\u003C+2SD (adolescents) or BMI 25-34.9 kg\u002Fm2 (seniors)\n* Waist circumference \\> 80 cm for women and \\> 94 cm for men (seniors)\n* FBG 5.6-6.9 mmol\u002FL (prediabetes)\n* Willing to follow Canada's Food Guide\n* Willing to maintain current dietary supplement use throughout the study.\n* Willing to abstain from alcohol consumption for 24 hours before all test visits.\n* Willing to avoid vigorous physical activity for 24 hours before all test visits.\n* Understands the study procedures and is willing to provide informed consent by the parent\u002Fguardian and assent by participant to participate in the study and authorization to release relevant protected health information to the study investigator.\n\nExclusion Criteria:\n\n* Fasting BG ≥ 7 mmol\u002FL\n* Blood pressure systolic ≥ 130mmHg or diastolic ≥ 80mmHg (adolescents) or systolic ≥ 140 mmHg or diastolic pressure ≥ 90 mmHg\n* Smoking (tobacco and\u002For cannabis product use in the last 6 months)\n* Thyroid problems\n* History of CVDs, diabetes, liver or kidney disease, inflammatory bowel disease, celiac disease, short bowel syndrome, any malabsorption syndrome, pancreatitis, gallbladder, or biliary disease.\n* Presence of gastrointestinal disorder or surgeries within the past year.\n* Use of the prescription or non-prescription drugs, herbal or nutritional supplements known to affect the outcome of the study as per the investigator's judgment (including prebiotics and probiotics).\n* Known to be pregnant, lactating, or not postmenopausal for at least a year and\u002For is taking hormonal treatments\n* Unwillingness or inability to comply with the experimental procedures\n* Known intolerance, sensitivity, or allergy to dairy, gluten, or any other study treatments.\n* Consumption of protein powders\u002Fsupplements\n* Extreme dietary habits (e.g., Atkins diet, very high-protein diets, etc.)\n* Weight gain or loss of \\> 5% in the previous three months.\n* Excessive alcohol intake (more than 2 drinks per day or 9 per week)\n* Restrained eating, identified by a score of ≥11 on the Eating Habits Questionnaire\n\nInclusion Criteria (short-term study):\n\n* Age 14-18 years old (adolescents) or 60-75 years old (older adults)\n* BMI z-score \\>+1SD, \\\u003C+2SD (adolescents) or BMI 25-30 kg\u002Fm2 (older adults)\n* Willing to maintain habitual diet, physical activity pattern, and body weight throughout the study.\n* Willing to maintain current dietary supplement use throughout the study. On study visit days, subject agrees not to take any supplements until dismissal from the Nutrition Intervention Center.\n* Willing to abstain from alcohol consumption for 24hrs prior to all study visits.\n* Willing to avoid vigorous physical activity for 24hrs prior to all study visits.\n* Willing to refrain from cannabis use throughout the entire duration of the study.\n* Willing to refrain from protein supplement use (e.g. protein powder) throughout the entire duration of the study.\n* Understands the study procedures, provides informed consent to participate in the study, and authorizes release of relevant protected health information to the study investigator.\n\nExclusion Criteria (short-term study):\n\n* Smoking\n* Thyroid problems\n* Lactose intolerance and\u002For allergies, intolerances, or sensitivities to study treatments\n* Previous history of cardiovascular disease, diabetes, liver or kidney disease, inflammatory bowel disease, celiac disease, short bowel syndrome, malabsorptive syndrome, pancreatitis, gallbladder or biliary disease\n* Presence of gastrointestinal disorder or surgeries within the past year.\n* Inability to comply with the experimental procedures and follow our safety guidelines\n* Regular breakfast skipping (\\>3 days a week)\n* On a special diet (e.g. ketogenic, Atkins, high protein) or restrained eaters as identified by a score of \\>20 on the Eating Attitudes Questionnaire\n* Difficulties with eating or swallowing\n* Fasting blood glucose \\>5.6mmol\u002FL measured at screening\n* Uncontrolled hypertension (systolic blood pressure \\>120mmHg, diastolic blood pressure \\>80mmHg) as defined by the average blood pressure measured at screening\n* Weight gain or loss of \\>10lbs in previous three months\n* Consuming prescription or non-prescription drug, herbal or nutritional supplements known to affect outcome of the study as per investigator's judgement","14 Years",{"count":256,"type":21},240,[24],"The goal of this study is to examine how regular dairy intake affects body weight, body composition, and metabolic health in overweight and obese adolescents (ages 15-18) and older adults (ages 60-80) over six months. We are inviting eligible individuals to participate in this study at the Nutrition Intervention Center, Department of Nutritional Sciences, University of Toronto. Participants will be randomly divided into two groups. The intervention (dairy) group will consume three servings of dairy per day (milk, yogurt, and cheese) before breakfast, lunch, and dinner. The control (low-dairy) group will continue their usual diet, keeping dairy intake to less than one serving per day.\n\nParticipants will have biweekly sessions with a registered dietitian to be guided to follow Canada's Food Guide, monitor their dietary intake and ensure compliance with their assigned group. In addition, they will visit the Nutrition Intervention Center at weeks 0, 12, and 24 for anthropometric and body composition assessments (weight, height, waist circumference, blood pressure, lean mass, and fat mass), resting metabolic rate, (gait speed, grip strength, and chair stand test just for older adults) and blood markers (fasting blood glucose, insulin, C-peptide, HbA1c, lipid profiles, and inflammatory markers). Each visit will take approximately 4 hours.\n\nBefore each visit, the participants will be asked to fast overnight for 12 hours, maintain their usual diet and sleep patterns, and avoid exercise and alcohol the day before. The participants will be compensated for their time and travel expenses.\n\nOur secondary objective is to compare the effects of dairy and plant-based alternative products on blood sugar and appetite regulation in adolescents and older adults. Participants will be asked to come to the Nutrition Intervention Center on 3 separate occasions: once for an in-person screening lasting approximately 30 min and 2 times for study visits lasting approximately 2.5 hrs each. The entire study will take at least 2 weeks to complete. You will be asked to fast for 12 hrs (overnight) before each study visit. You will also be instructed to maintain the same dietary and sleep patterns and refrain from exercise and alcohol consumption on the days before the study visits. During these study visits, you will be asked to consume either a dairy or a plant-based alternative product as well as a pizza meal. You will periodically fill out questionnaires rating your feelings and perceptions, and provide blood samples through finger pricks and intravenously through your forearm to measure blood sugar, insulin, hormones, and amino acids. You will be compensated for your time and travel expenses.",[260,182,261],"Dairy Consumption","Obesity Prevention",[263,28,264,265,266,267,268,269],"Dairy intake","Type2 Diabetes","HbA1c","BMI z-score","Insulin resistance","Adolescents","Seniors","2026-03-03",{"date":272,"type":39},"2026-03-05",{"date":274,"type":21},"2026-06-01",{"date":276,"type":21},"2028-06",{"name":45,"class":46},{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":284,"eligibilityCriteria":285,"healthyVolunteers":56,"sex":17,"minAge":143,"maxAge":206,"enrollmentInfo":286,"targetDuration":4,"studyType":22,"phases":288,"briefSummary":290,"conditions":291,"keywords":294,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":47},"100591039","phase-4-observing-metabolism-of-epa-with-consideration-of-genetics-and-sex-100591039","NCT06975241","Observing Metabolism of EPA With Consideration of Genetics And Sex","Determining Contribution of Sex and Genetics to DHA Synthesis Rates Over 12 Weeks of EPA Supplementation in Healthy Individuals","OMEGA","Inclusion Criteria:\n\n* BMI between 18.5- 30 kg\u002Fm2\n* healthy\n\nExclusion Criteria:\n\n* Consumption of fish\u002Fseafood or EPA\u002FDHA-enriched foods currently or within the previous 6 months\n* Consumption of any supplements containing ALA\u002FEPA\u002FDHA currently or within the previous 6 months\n* Allergies to any component of the study supplement (fish, gelatin etc.)\n* BMI \\\u003C18.5 kg\u002Fm² or \\>30 kg\u002Fm²\n* Women who are pregnant, breastfeeding or planning on becoming pregnant\n* Diagnosis with chronic or communicable diseases\n* Prescription of chronic pharmacological medications (except for oral contraceptives)\n* High blood pressure (systolic or diastolic blood pressure above 130 or 80mmHg, respectively)\n* Hypertriglyceridemia (serum \\> or = 1.69 mmol\u002Fl)\n* Hypercholesterolemia (serum LDL-C \\> or =5 mmol\u002Fl)\n* Anticipated changes in lifestyle within the next 4 months\n* Smoking\n* Heavy alcohol use (\\>3 drinks\u002Fday)\n* Major surgery in the last six months",{"count":287,"type":21},64,[289],"PHASE4","The goal of this clinical study is to learn how fast EPA is converted to other molecules, including DHA, with consideration of biological sex and genetics in healthy humans.\n\nThe main questions it aims to answer are:\n\n* How fast is EPA converted to DHA in blood, and is the conversion rate affected by sex and a specific genotype we previously identified?\n* How do sex and the specific genotypes affect blood DHA levels and other products of DHA in response to dietary EPA?\n* How fast does dietary EPA replace blood EPA and other omega-3 fatty acids, and is the rate affected by sex and genotype?\n\nParticipants will be asked to take EPA supplements for 12 weeks and provide a series of venous blood samples over the study duration.",[212,292,293],"Omega 3","Metabolism, Lipids",[295,296,297,298,299,300,301],"eicosapentaenoic acid","omega-3 polyunsaturated fatty acids","lipid metabolism","healthy adults","docosahexaenoic acid","single nucleotide polymorphism","elongation of very long-chain 2","2026-02-25",{"date":304,"type":39},"2026-02-27",{"date":306,"type":39},"2025-07-29",{"date":308,"type":21},"2026-09",{"name":45,"class":46},{"id":311,"slug":312,"hasResults":12,"nctId":313,"briefTitle":314,"officialTitle":314,"acronym":315,"eligibilityCriteria":316,"healthyVolunteers":56,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":317,"targetDuration":4,"studyType":22,"phases":319,"briefSummary":321,"conditions":322,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":47},"100596807","phase-3-post-operative-urinary-retention-on-revision-knee-arthroplasty-the-role-of-intrathecal-morphine-100596807","NCT07050277","Post-Operative Urinary Retention on Revision Knee Arthroplasty: the Role of Intrathecal Morphine","POURRKA","Inclusion Criteria:\n\n* Non pregnant patients undergoing unilateral non infected rTKA surgery;\n* Older than 21 years of age, with American Society of Anesthesiologists (ASA) physical status I-III;\n* With no alcohol or drug dependency history;\n* With sufficient understanding and co-operation about the usage of a perineural catheter for pain management; body mass index (BMI) under 45;\n* With no allergy to medications used in the study protocol (bupivacaine, lidocaine, ropivacaine, midazolam, propofol, ketamine, morphine, hydromorphone, fentanyl, acetaminophen, celecoxib, ondansetron, dexamethasone, tranexamic acid);\n* No current or recent use of opioids (within the last 2 weeks) in an average oral morphine equivalent (OME) of 20 mg\u002Fday or higher;\n* With no contra-indications for neuraxial anesthesia, IPACK block, ACB and adductor canal catheter insertion;\n* Who speak and understand the English language;\n* Who agrees to participate on this study through the signature of the consent form.\n\nExclusion Criteria:\n\n* Patients will be excluded of the study if they have a failed spinal anesthesia and needs for a conversion to general anesthesia;\n* If peripheral nerve blocks are not possible to be performed due to technical difficulties;\n* If during patient's care a deviation of the protocol occurs;\n* If CACB catheter has issues on its function, disconnects or exteriorizes within the first 48 hours of infusion;\n* Or if patient decides to withdraw from the study.",{"count":318,"type":21},50,[320],"PHASE3","Revision total knee arthroplasty (rTKA) is a frequently performed procedure. Adequate pain management is an important feature, especially for fast-track and Enhanced Recovery After Surgery (ERAS) programs. The multimodal approach, including single shot or continuous nerve blocks with catheters and spinal or epidural morphine, is a stablished strategy. Although the administration of intrathecal morphine (IM) has been shown to significantly reduce pain scores, it is not free of adverse effects. Postoperative urinary retention (POUR) is possible and might increase the risk of periprosthetic infection. The purpose of this study is to compare patients undergoing rTKAS under spinal anesthesia with IM to patients undergoing the same procedure, under the same anesthetic technique, but with no IM, for POUR and postoperative pain related outcomes. All patients will have single shot and continuous adductor canal block (CACB) and single shot IPACK (interspace between the popliteal artery and the posterior knee capsule) block. The hypothesis is that postoperative pain control is comparable between the groups, with lower incidence of POUR in patients with no IM given.",[323,324,325,326],"Arthroplasties, Knee Replacement","Nerve Block","Urinary Retention Postoperative","Anesthesia, Spinal","2025-12-19",{"date":329,"type":39},"2025-12-29",{"date":331,"type":39},"2025-06-24",{"date":333,"type":21},"2027-08-01",{"name":45,"class":46},{"id":336,"slug":337,"hasResults":12,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":341,"eligibilityCriteria":342,"healthyVolunteers":56,"sex":17,"minAge":143,"maxAge":206,"enrollmentInfo":343,"targetDuration":4,"studyType":22,"phases":345,"briefSummary":346,"conditions":347,"keywords":349,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":47},"100617384","validating-iaao-for-muscle-outcomes-100617384","NCT07317921","Validating IAAO for Muscle Outcomes","Validating the Indicator Amino Acid Oxidation Technique for Muscle Outcomes","VIM","Inclusion Criteria:\n\n* Participants will be aged 18-35 years old\n* Participants will have a BMI within the normal range (i.e., 18.5-24.9) and waist-to-hip circumference ratio of \\\u003C0.95 for males and \\\u003C0.8 for circumference for females to ensure homogeneity of the sample population\n* Participants are willing to abide by the compliance rules of this study (e.g., abstain from extraneous physical activity 48h prior to session 4\n* Self-reported regular menstrual cycle (25-35d) within the last 3 months (female participants)\n* Physical activity score of ≥24 units as measured by the Godin leisure time exercise questionnaire\n\nExclusion Criteria:\n\n* Inability to adhere to any of the compliance rules judged by principal investigator\n* Self-reported regular tobacco or illicit drug use (e.g., growth hormone or testosterone)\n* Current use of hormonal contraceptives\n* Individuals with a history of allergy to local anesthetics (e.g., lidocaine)",{"count":344,"type":21},8,[24],"Consuming dietary protein stimulates whole-body and muscle protein synthesis, the latter of which is typically measured using invasive primed constant infusions of stable isotopes with concurrent muscle biopsies. Alternative non-invasive methodologies have been developed (namely the indicator amino acid oxidation (IAAO) technique) to estimate the impact of protein ingestion on whole-body protein synthesis as a proxy for determining dietary protein requirements. Given that the IAAO technique is based on principles of protein metabolism which occur in the liver, it is unclear how representative the IAAO outcomes of whole-body protein synthesis is to skeletal muscle protein synthesis. Validation of the IAAO technique against gold-standard, biopsy-derived measures of muscle metabolism (i.e., muscle protein synthesis) would assist in mitigating the invasiveness of muscle physiology and nutrition research.",[348],"Protein Metabolism",[350,348,351,352,353,354],"Muscle biopsy","Stable isotopes","Protein oxidation","Indicator amino acid oxidation","Protein synthesis","2025-12-18",{"date":357,"type":39},"2026-01-05",{"date":359,"type":39},"2025-12-01",{"date":361,"type":21},"2026-05-20",{"name":45,"class":46},{"id":364,"slug":365,"hasResults":12,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":369,"eligibilityCriteria":370,"healthyVolunteers":56,"sex":205,"minAge":143,"maxAge":18,"enrollmentInfo":371,"targetDuration":4,"studyType":22,"phases":373,"briefSummary":374,"conditions":375,"keywords":379,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":47},"100612822","menstrual-cycle-vs-oral-contraceptives-effects-on-muscle-protein-metabolism-after-resistance-exercise-100612822","NCT07258576","Menstrual Cycle vs. Oral Contraceptives: Effects on Muscle Protein Metabolism After Resistance Exercise","The Effect of Menstrual Cycle Phase and Oral Contraceptive Use on Muscle Protein Metabolism Post-Resistance Training","MCOC","Inclusion Criteria:\n\n* Age: 18-40 years\n* BMI between 18.5-29.9 kg\u002Fm2 (non-obese)\n* Recreationally active (resistance train minimum twice a week)\n* Using monophasic or triphasic oral contraceptives for \\>1 year (for oral contraceptive users)\n* Have regular menstrual cycles (21-35 days) for the past 3 months and discontinued any hormonal contraceptive use for at least 6 months (non-oral contraceptive users)\n* Must meet a progesterone sufficiency test (non-oral contraceptive users)\n\nExclusion Criteria:\n\n* Mid-luteal progesterone levels \\\u003C16umol\n* Chronic disease diagnosis (cardiovascular, thyroid, diabetes)\n* Current or recent remission of cancer\n* Regular use of non-steroidal anti-inflammatory drugs (NSAIDs; except low-dose aspirin), anticoagulants\n* Use of prescription drugs that would impact muscle protein synthesis, e.g. Statins, Lithium, ADHD medication.\n* Insertion of intrauterine device (IUD) - exception: copper\n* Use of emergency contraception in the last 3 months (e.g. Plan B)\n* Severe food allergies (e.g. soy, nuts)\n* Smoking, use of performance enhancing drugs (growth hormones, testosterone)",{"count":372,"type":21},20,[24],"The muscles of the body are constantly breaking down old proteins and building new ones. These two processes, protein breakdown and protein synthesis, together are known as protein turnover. Protein turnover is essential for maintaining healthy muscle.\n\nDespite its importance, females have historically been underrepresented in protein metabolism research. A long-standing assumption has been that fluctuations in female sex hormones such as estrogen and progesterone, whether across the natural menstrual cycle or in individuals using oral contraceptives (OCs), make metabolism and training responses too variable to study. Because of this, many researchers have excluded female participants for logistical reasons.\n\nResistance exercise, such as weightlifting, is the most effective way to increase muscle size and strength. Each resistance-training session triggers muscle protein synthesis (MPS), the process by which new muscle proteins are built. Consuming dietary protein or individual amino acids further increases the rate at which new proteins are formed. Over time, higher rates of protein synthesis support muscle growth and the maintenance of other lean tissues in the body.\n\nThe purpose of this study is to examine how menstrual cycle phases and OC use influence the synthesis of proteins in both muscle tissue and the rest of the body. Improving scientific understanding in this area will support more effective, evidence-based training and nutrition recommendations for females.",[376,377,378,348],"Female Sex Hormones","Menstrual Cycle","Oral Contraceptives",[348,376,377,378,380,381,382,383],"Resistance Exercise","Weightlifting","Indicator Amino Acid Oxidation","Stable Isotope Tracer","2025-11-28",{"date":386,"type":39},"2025-12-02",{"date":388,"type":39},"2025-07-20",{"date":390,"type":21},"2026-09-01",{"name":45,"class":46},{"id":393,"slug":394,"hasResults":12,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":398,"eligibilityCriteria":399,"healthyVolunteers":56,"sex":205,"minAge":4,"maxAge":4,"enrollmentInfo":400,"targetDuration":4,"studyType":22,"phases":401,"briefSummary":402,"conditions":403,"keywords":407,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":47},"100564761","alternative-physical-activity-strategies-for-breast-cancer-survivors-100564761","NCT06633380","Alternative Physical Activity Strategies for Breast Cancer Survivors","Alternative Physical Activity Strategies for Breast and Prostate Cancer Survivors","PACE","Inclusion Criteria:\n\n* Postmenopausal biological females diagnosed with stage I, II, or III breast cancer and currently using aromatase inhibitors (AI) for at least 3 months prior to start of study participation\n* All participants must meet the following criteria:\n\n  * Body mass index equal to or greater than 25 kg\u002Fm\\^2.\n  * Self-report consuming three main meals daily.\n  * Self-report as being sedentary (i.e., less than 30 minutes\u002Fweek of moderate-to-vigorous aerobic physical activity and less than twice\u002Fweek muscle strengthening of major muscle groups in the last three months.\n\nExclusion Criteria:\n\n* If unable or unwilling to receive medical clearance by a physician after being screened for major signs or symptoms of cardiovascular diseases, diabetes, or renal disease and safety to initiate exercise.\n\n  * Major signs or symptoms of cardiovascular diseases, diabetes, or renal disease are taken from the American College of Sports Medicine's Guidelines for Exercise Testing and Prescription 11th edition Table 2.1. They include pain or discomfort in the chest, neck, jaw, arms with rest or exercise, shortness of breath at rest or with mild exertion, dizziness or syncope, ankle edema, palpitations or tachycardia, intermittent claudication, known heart murmur, and unusual fatigue with usual activities.\n  * Safety to initiate exercise will be screened using the Get Active Questionnaire, which is the Canadian Society of Exercise Physiology's endorsed evidence-based pre-screening tool.\n* Using drugs for diabetes management (e.g., exogenous insulin, Ozempic, metformin, etc.) or actively losing weight (i.e., \\>5 kg weight loss in past 3 months) from drugs or other reasons\n* Report any injury or other reason for not feeling capable of completing a 30 minute continuous walk or muscle strengthening exercise\n* Unable to access an Ontario Lifelabs location for an overnight fasted blood draw\n* Do not have a smartphone compatible with the applications required to collect data.\n* Cannot read and understand the consent form or communicate in English.",{"count":208,"type":21},[24],"The primary aim of this study is to compare the acute glycemic effects of two novel, alternative physical activity (PA) strategies (dispersed post-meal PA, PA snacks) to a no PA condition and to exercise sessions representing the PA guidelines (standard 30-minute walking bout performed under fasting and under postprandial conditions and a standard 30-minute resistance training session) among sedentary breast cancer survivors who are currently receiving hormone therapies and age- and BMI-matched postmenopausal women without a history of cancer. The secondary aim is to determine whether the alternative PA strategies are acceptable and feasible in the free-living setting. An exploratory aim is to determine whether the outcomes differ between women with and without a history of breast cancer and use of aromatase inhibitors.\n\nThe investigators hypothesize that:\n\n1. Dispersed PA and PA snacks will result in greater reductions in 24-hour glucose and postprandial glucose compared to the no-PA baseline and similar reductions to a standard 30-minute bouts of walking;\n2. The alternative PA strategies will be more feasible and have greater acceptability by cancer survivors compared to the standard 30-minute bout of walking or resistance training; and\n3. The different PA strategies will have similar effects on glycemic outcomes for both breast cancer survivors and cancer-free controls. The resistance exercise session is an exploratory trial as the effects of it on acute glycemic control are understudied.",[404,405,406],"Breast Cancer","Insulin Resistance","Cardiometabolic Risk Factors",[408,409,34],"Physical Activity","Hormone Therapy","2025-11-24",{"date":386,"type":39},{"date":413,"type":39},"2024-10-22",{"date":415,"type":21},"2026-07-01",{"name":45,"class":46},{"id":418,"slug":419,"hasResults":12,"nctId":420,"briefTitle":421,"officialTitle":421,"acronym":422,"eligibilityCriteria":423,"healthyVolunteers":12,"sex":205,"minAge":424,"maxAge":425,"enrollmentInfo":426,"targetDuration":4,"studyType":22,"phases":428,"briefSummary":429,"conditions":430,"keywords":434,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":443,"locationsCount":47},"100612888","time-restricted-eating-in-survivors-trial-20-100612888","NCT07259434","Time Restricted Eating in Survivors Trial 2.0","TEST2","Inclusion Criteria:\n\n* female\n* aged 60-85 years\n* BMI ≥25 kg\u002Fm2\n* diagnosed with early-stage (I-III) BC in the past 15 years\n* received chemotherapy treatment that was completed ≥1 year earlier\n* Montreal Cognitive Assessment (MoCA) score of 10-30 which aligns with no impairment to moderate impairment thresholds.\n\nExclusion Criteria:\n\n* does not have a mobile device that connects to Bluetooth and can send\u002Freceive text messages\n* history of physician-diagnosed heart disease, dementia or Alzheimer's disease, diabetes that requires insulin or sulfonylurea usage, or eating disorder\n* MoCA total score \\\u003C10 (indicating dementia)\n* ≥5kg weight change within past 3 months\n* taking lipid- or weight-lowering medication (e.g. statins or GLP-1 agonists)\n* high-risk for malnutrition (≥3 on the Malnutrition Screening Tool)\n* research MRI contraindications (e.g., pacemaker, breast tissue expander, magnetic implants)\n* eating all daily calories in \\\u003C10h\u002Fd in the past 3 months\n* following a structured dietary practice (e.g., ketogenic diet, Weight Watchers) or actively trying to lose weight in the past 3 months\n* being unable to make adjustments to eating time or nutrient intake\n* regularly doing \\>90 min\u002Fweek of moderate physical activity in the past 3 months\n* severe claustrophobia\n* BMI\\>40 kg\u002Fm2 (due to body habitus fit within MRI scanner bore)\n* major psychiatric disorders (e.g. bipolar, post-traumatic stress disorder, schizophrenia)\n* neurological disorders that significantly impact physical or cognitive function (epilepsy, stroke, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, muscular dystrophy) or traumatic brain injury resulting in ongoing neurological deficits. If the screening process identifies patients with undiagnosed severe cognitive function (MoCA score \\\u003C10) or at high risk for malnutrition (≥3 on the Malnutrition Screening Tool), the investigators will recommend that the individual see their family physician. In this process, the investigators will ask the participant if there is a family member that can also receive this information.","60 Years","85 Years",{"count":427,"type":21},152,[24],"After chemotherapy, older breast cancer survivors experience a faster decline in brain function. This can make it harder to enjoy life, stay social, and maintain independence. Chemotherapy can lead to poorer lifestyle habits, like unhealthy eating, less exercise, high stress, and poor sleep. Chemotherapy can also affect important health markers like blood sugar and cholesterol. Over time, these changes can damage blood vessels, which might lead to heart and brain issues. The investigators do not fully understand why brain function declines faster after chemotherapy, especially in older survivors, because there are many factors involved. In this study, the investigators will look at how lifestyle habits (like diet, exercise, stress and sleep), health markers (like blood sugar and cholesterol), and blood vessel health (like how well blood flows and how stiff the blood vessels are) affect brain function in older breast cancer survivors. The investigators will include 152 females aged 60-85 years, who finished chemotherapy for early-stage breast cancer at least 1 year ago. The investigators will use special tests to check different parts of brain function, like language, memory, and attention, as well as brain blood vessel health. This will help to understand which factors might speed up or slow down memory and thinking problems. Since many Canadian breast cancer survivors experience faster decline in brain function after chemotherapy, this study aims to find out what might make it worse. The results could help to create better and more personalized treatment plans for older breast cancer survivors that protect brain health and reduce problems with brain function in the future.",[404,431,432,433],"Cardiovascular Risk","Cognitive Function","Physical Function",[435,436],"Treatment","Prevention","2025-11-20",{"date":386,"type":39},{"date":440,"type":21},"2026-01-01",{"date":442,"type":21},"2028-10-31",{"name":45,"class":46},{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":450,"eligibilityCriteria":451,"healthyVolunteers":12,"sex":17,"minAge":452,"maxAge":4,"enrollmentInfo":453,"targetDuration":4,"studyType":22,"phases":455,"briefSummary":456,"conditions":457,"keywords":461,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":467,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":47},"100586740","the-effect-of-a-digital-heart-health-app-and-lifestyle-intervention-for-heart-disease-in-primary-care-100586740","NCT06919302","The Effect of a Digital Heart Health App and Lifestyle Intervention for Heart Disease in Primary Care.","An Innovative Technology-based Approach to Translating Clinical Practice Guidelines of Nutrition Therapy in Primary Care: The Coronary Heart Effectiveness Assessment of the Portfolio Diet in Primary Care (CHEAP) Trial","CHEAP","Inclusion Criteria:\n\n* Be taking statin medication with or without other antihyperlipidemic therapy (stable dose for at least 3-months).\n* Fall under either of the 2 categories:\n\n  1\\) Secondary prevention participants: males and females ≥45 years of age with established atherosclerotic cardiovascular disease (ASCVD) defined as at least one of the following: i. Prior myocardial infarction (MI); ii. Acute coronary syndrome (ACS); iii. Stroke\u002FTIA; iv. Coronary revascularization; v. Documented carotid disease (endarterectomy, carotid stenosis ≥50%); vi. Stable angina; vii. Coronary artery disease (CAD) by angiography; viii. Peripheral artery disease (PAD); ix. Abdominal aortic aneurysm (AAA)\n\n  2\\) High-risk primary prevention participants: males and females ≥50 years of age plus type 2 diabetes requiring treatment with medication and at least one additional risk factor: i. Males ≥55 years of age and females ≥65 years of age; ii. Cigarette smoker or stopped smoking within 3 months before Visit 1; iii. Hypertension and on antihypertensive medication for at least 6-months; iv. Chronic kidney disease (CKD); v. Retinopathy, defined as any of the following: non-proliferative retinopathy, pre-proliferative retinopathy, proliferative retinopathy, maculopathy, advanced diabetic eye disease or a history of photocoagulation\n* Be on a stable dose for at least 3-months of all antihyperlipidemic, antihyperglycemic, antihypertensive, and antiobesity therapies.\n* Have a family physician in Ontario and a valid Ontario Health Card.\n* Have regular access to an online portal\n* Be proficient in English.\n\nExclusion Criteria:\n\n* Major disease expected to result in death within 2 years (except cardiovascular disease)\n* Active sever liver disease\n* Malabsorption disorders\n* Drug or alcohol abuse disorders (within past 6 months)\n* Intolerance or allergies to soy protein and tree nuts, peanuts, or seeds\n* Planned coronary intervention or any major surgical procedure\n* Participation in another clinical trial (within past 3 months)\n* End stage renal disease (requirement for peritoneal dialysis or hemodialysis for renal insufficiency or eGFR \\\u003C30 mL\u002Fmin)\n* Any condition or therapy which might pose a risk to the patient or make participation in the study not be in the best interest of the patient as assessed by the investigator\n* Documented severe (New York Heart Association \\[NYHA\\] class IV) heart failure\n* Mental\u002Fpsychological impairment expected to affect adherence to the study protocol\n* Known AIDS (HIV-positive patients without AIDS are allowed)\n* Women planning on becoming pregnant within the first year of the intervention\n* Unable to provide informed consent: Appear unable to comprehend the study protocol during the interview process or to understand and communicate in English sufficiently for informed consent.","45 Years",{"count":454,"type":21},1100,[24],"Despite the availability of medications, many people around the world continue to live with long-term health problems like heart disease, stroke and diabetes. In Canada, heart disease is a leading cause of death. Managing these health issues can be done by changing diet and lifestyle. Specific ways of eating have been proven to improve risk for heart disease and stroke. However, because doctors often have limited time, nutrition education, and lack of tools for counseling patients on nutrition, they can often only provide minimal support to help patients make necessary lifestyle changes. Digital tools and mobile applications offer an opportunity to involve doctors and patients in delivering nutrition interventions. This approach has the potential to save time, provide education, and reduce healthcare costs. This study is being done to understand the effect of a digital heart health program added to standard of care, compared with standard of care alone on heart health. All eligible participants in this study will be randomized (determined by chance) to one of two possible interventions: 1) a digital heart health program + standard of care; 2) standard of care. Standard is care is defined as the best practice based on guidelines for the treatment of a condition. All participants will be followed for seven years and will be asked to complete online questionnaires and complete blood work at their nearest LifeLabs clinic, as well as wear a continuous glucose monitor and wrist actigraph (at 3 time points in the first year). In addition, participants randomized to the digital heart health program + standard of care will be expected to use the heart health app and join 16 online synchronous sessions over the first year.\n\nAfter seven years, the intervention phase of the study will end and the study will become a cohort study. All participants at the 7-year time point will be invited to use the heart health app. As part of the cohort study, participants will be asked to continue completing the same questionnaires online and completing bloodwork at their nearest LifeLabs every four years for the duration of their participation in the cohort study.\n\nThe main questions this study aims to answer are:\n\n1. Will a digital heart health program added to standard of care result in a clinically meaningful reduction in blood cholesterol and other risk factors after 1-year compared to standard of care alone?\n2. Will a digital heart health program added to standard of care result in a reduction in major cardiovascular events after 7-years compared to standard of care alone?\n3. Are the observed effects sustained beyond the 7-years of the intervention?\n\nWe hypothesize that the digital heart health program added to standard of care will result in a clinically meaningful reduction in blood cholesterol and other risk factors for heart disease after 1-year and reduce major cardiovascular events after 7-years compared to standard of care alone.",[458,183,180,459,460],"Cardiovascular Diseases","Cholesterol","Major Cardiovascular Event",[462,463,464,465,466],"randomized controlled trial","digital heart health program","heart health app","web-based app","large-scale study",{"date":468,"type":39},"2025-11-26",{"date":470,"type":39},"2025-08-15",{"date":472,"type":21},"2035-06-01",{"name":45,"class":46},{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":480,"eligibilityCriteria":481,"healthyVolunteers":56,"sex":205,"minAge":4,"maxAge":4,"enrollmentInfo":482,"targetDuration":4,"studyType":483,"phases":4,"briefSummary":484,"conditions":485,"keywords":487,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":491,"startDateStruct":493,"completionDateStruct":495,"leadSponsor":497,"locationsCount":47},"100576166","short-term-impacts-of-endocrine-therapy-on-cardiovascular-and-brain-health-outcomes-in-breast-cancer-100576166","NCT06781762","Short-term Impacts of Endocrine Therapy on Cardiovascular and Brain Health Outcomes in Breast Cancer","Beyond Cardiotoxicity: Characterizing the Short-term Cardiovascular Side Effects of Breast Cancer Endocrine Treatment","STRIVE (Acute)","Inclusion Criteria:\n\nCase group:\n\n* Biologically female\n* Post-menopausal with natural (no bilateral oophorectomy) amenorrhea for at least 1 year\n* If using hormone replacement therapy, limit of a maximum of 3 years of treatment but not within the last 6 months.\n* Diagnosis of stage I, II, or III breast cancer\n* Hormone receptor positive breast cancer\n* HER negative (ER+\u002FPR+\u002FHER-) breast cancer\n* Confirmed to start aromatase inhibitor therapy for the first time in next 2-3 months\n* Received surgery\u002Fradiation therapies\n\nControl group:\n\n* Biologically female\n* Post-menopausal with natural (no bilateral oophorectomy) amenorrhea for at least 1 year\n* If using hormone replacement therapy, limit of a maximum of 3 years of treatment but not within the last 6 months.\n\nExclusion Criteria:\n\n* Previous treatment using tamoxifen endocrine therapy in a pre-or peri-menopausal setting\n* Major signs or symptoms of cardiovascular diseases, diabetes, or renal disease (taken from the American College of Sports Medicine's Guidelines for Exercise Testing and Prescription 11th edition Table 2.1: pain or discomfort in the chest, neck, jaw, arms with rest or exercise, shortness of breath at rest or with mild exertion, dizziness or syncope, loss of balance or passing out, ankle edema, palpitations or tachycardia, intermittent claudication, known heart murmur, unusual fatigue with usual activities.)\n* American Heart Association's absolute or relative contraindications for symptom-limited maximal exercise testing (myocardial infarction, aortic or coronary artery stenosis, heart failure, pulmonary embolism or deep vein thrombosis, inflammation of the heart (myocarditis, pericarditis, and\u002For endocarditis), uncontrolled cardiac arrythmia, advanced or complete electrical heart block, stroke or transient ischemia attack, blood pressure \\>200mmHg\u002F100mmHg, a cancer diagnosis other than skin cancer)\n* Unable to provide informed consent or communicate in English\n* Mobility limitations to exercise testing (i.e., wheelchair, walker use, limp impeding walking)\n* Extreme claustrophobia",{"count":117,"type":21},"OBSERVATIONAL","Aromatase inhibitors are the most used endocrine therapy for hormone-positive breast cancer. While there is a clear linear relationship between the duration of aromatase inhibitor use and the cumulative incidence of cardiovascular events and mortality, the underlying mechanisms contributing to this risk remain unknown. This study will characterize the short-term effects of aromatase inhibitor therapy on established and novel health indices for cardiovascular diseases in breast cancer patients.\n\nUsing a longitudinal case-control design this study will assess the effects of short-term (first 6 months) aromatase inhibitor use in breast cancer patients compared to age- and BMI-matched controls, aiming to determine the cardiovascular, metabolic, and behavioural health impacts of endocrine treatment during this early period. Specifically, our objectives are as follows:\n\n1. To examine the effects of aromatase inhibitor therapy on early risk indicators for cardiovascular disease in the peripheral vasculature and heart, including blood biomarkers (lipids), blood pressure, aortic and peripheral stiffness, carotid artery stiffness and intima media thickness, endothelial function, and left ventricular ejection fraction, longitudinal strain, volumes, and mass, including the responsiveness of the cardiovascular system to an oral glucose tolerance test, in breast cancer survivors compared to controls.\n2. To examine the effects of aromatase inhibitor therapy on factors related to cerebrovascular health, autonomic regulation, and cognitive function, including BDNF, heart rate variability, cerebrovascular function in response to a supine-sit-stand maneuver and squatting challenge, and a core battery of cognitive function tests, in breast cancer survivors compared to controls.\n3. To examine the effects of aromatase inhibitor therapy on body composition and bone mineral density, along with assessments of glycemic regulation in response to an oral glucose tolerance test and in 24h periods of free-living (continuous glucose monitoring), in breast cancer survivors compared to controls.\n4. To examine the effects of aromatase inhibitor therapy on lifestyle factors (behavioural), including diet, physical activity (including cardiorespiratory fitness), sleep, stress, and quality of life, in breast cancer survivors compared to controls.\n\nThe investigators hypothesize that cardiovascular and metabolic health outcomes will be similar between breast cancer survivors and controls at baseline but will deteriorate relative to controls within the first 6 months of aromatase inhibitor therapy.",[486],"Breast Cancer Females",[488,486,489,28],"Aromatase Inhibitors","Heart Disease Risk Factors","2025-09-26",{"date":492,"type":39},"2025-10-01",{"date":494,"type":39},"2025-06-06",{"date":496,"type":21},"2026-12-30",{"name":45,"class":46},{"id":499,"slug":500,"hasResults":12,"nctId":501,"briefTitle":502,"officialTitle":503,"acronym":504,"eligibilityCriteria":505,"healthyVolunteers":12,"sex":205,"minAge":4,"maxAge":4,"enrollmentInfo":506,"targetDuration":4,"studyType":22,"phases":507,"briefSummary":508,"conditions":509,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":513,"startDateStruct":514,"completionDateStruct":516,"leadSponsor":518,"locationsCount":47},"100551036","multiple-risk-factor-intervention-trial-in-breast-cancer-survivors-100551036","NCT06454864","Multiple Risk Factor Intervention Trial in Breast Cancer Survivors","Multiple Risk Factor Intervention Trial In Breast Cancer Survivors","MsFITBC","Inclusion Criteria:\n\n* Biologically female\n* Diagnosis of stage I, II, or III breast cancer, post-menopausal at the time of diagnosis (haven't had a menstrual cycle within 12 months or greater)\n* Receipt of aromatase inhibitors for 12 months or more in the past, but do not have to be currently on aromatase inhibitors.\n* Willing and able to complete all study assessments\n* BMI ≥ 25 kg\u002Fm2\n* Able to commit to come to the University once per week for 24 weeks.\n\nExclusion Criteria:\n\n* Received chemotherapy within the past 11 months\n* Diagnosed with metastatic cancer\n* Currently taking tamoxifen\n* Currently receiving chemotherapy, targeted therapy or radiation treatment\n* Distant recurrence or diagnosis of metastatic cancer since early-stage breast cancer diagnosis\n* Diagnosed cardiovascular diseases, type 2 diabetes, non-alcoholic fatty liver disease, uncontrolled thyroid condition, or respiratory disease (e.g., COPD or severe or uncontrolled asthma).\n* Major signs or symptoms of cardiovascular diseases, diabetes, or renal disease (taken from the American College of Sports Medicine's Guidelines for Exercise Testing and Prescription 11th edition Table 2.1: pain or discomfort in the chest, neck, jaw, arms with rest or exercise, shortness of breath at rest or with mild exertion, dizziness or syncope, loss of balance or passing out, ankle edema, palpitations or tachycardia, intermittent claudication, known heart murmur, unusual fatigue with usual activities.)\n* American Heart Association's absolute or relative contraindications for symptom-limited maximal exercise testing (myocardial infarction, aortic or coronary artery stenosis, heart failure, pulmonary embolism or deep vein thrombosis, inflammation of the heart (myocarditis, pericarditis, and\u002For endocarditis), uncontrolled cardiac arrhythmia, advanced or complete electrical heart block, stroke or transient ischemia attack, blood pressure \\>200mmHg\u002F100mmHg, a cancer diagnosis other than skin cancer)\n* Unable to provide informed consent or communicate in English\n* Pregnant or breast-feeding currently or in the past 3 months\n* Mobility limitations to aerobic exercise (i.e., wheelchair, walker use, limp impeding walking)\n* Smoking cigarettes or marijuana within the past 3 months\n* Taking exogenous hormones in any format currently or in the past 3 months\n* Contraindications to research MRI (e.g., pacemaker, magnetic implants)\n* BMI exceeding 40 kg\u002Fm2\n* Extreme claustrophobia\n* Self-report \\>30 min\u002Fweek of moderate-to-vigorous intensity aerobic physical activity\n* Following a diet that largely restricts entire food groups or time of eating (e.g., vegan, ketogenic, carnivore, one meal a day) in last 3 months\n* Experienced significant weight loss (i.e., \\>5 kg) in past 3 months\n* Currently taking weight loss medications\n* Diagnosed history of an eating disorder or self-report of potential undiagnosed eating disorder\n* Plans to be away\u002Funavailable for a substantial period of the intervention overall (i.e., \\>4 weeks throughout the 6 months or \\>2 weeks within the first 12 weeks of the intervention).\n* Allergies to local anesthetics",{"count":84,"type":21},[24],"This study aims to produce new evidence on the efficacy of exercise and diet for cardiometabolic risk reduction in BC survivors. Using a 3-arm RCT with to 6 months of 1) exercise following Health Canada guidelines; 2) the same exercise plus counselling to follow Canada's Dietary Guidelines to improve diet quality; or 3) stretching group, this study will answer the following questions:\n\n* What is the impact of exercise on cardiometabolic health and body composition in BC survivors?\n* What is the effect modification of adding a diet quality intervention to exercise on cardiometabolic health and body composition?\n* Is there a link between the capacity of skeletal muscle adaptation to exercise (and diet) and insulin resistance in BC survivors?\n\nThe investigators hypothesize that: 1) exercise will improve cardiometabolic and body composition outcomes 2) improvements in cardiometabolic outcomes will be enhanced by the addition of diet quality, which will be essential or additive for Matsuda index, metabolic syndrome, Framingham CVD risk, thigh myosteatosis, muscle mass, VO2peak, 3) skeletal muscle insulin signalling transduction will be impaired in BC survivors via dampened expression of insulin-responsive proteins (e.g. GLUT4) and co-occur with impaired muscle quality (e.g., higher rates of fat depots, presence of fibrous tissue) negatively impacting insulin signalling.",[510,511,512],"Metabolic Disturbance","Sedentary Behavior","Breast Cancer Female",{"date":492,"type":39},{"date":515,"type":39},"2024-07-01",{"date":517,"type":21},"2027-04-01",{"name":45,"class":46},{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":524,"acronym":525,"eligibilityCriteria":526,"healthyVolunteers":12,"sex":205,"minAge":143,"maxAge":4,"enrollmentInfo":527,"targetDuration":4,"studyType":483,"phases":4,"briefSummary":529,"conditions":530,"keywords":531,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":536,"startDateStruct":537,"completionDateStruct":539,"leadSponsor":541,"locationsCount":47},"100479436","cardio-oncology-rehabilitation-exercise-100479436","NCT05522959","Cardio-Oncology Rehabilitation Exercise","A Single Arm Intervention Study to Assess the Role of Structured Cardio-Oncology Rehabilitation Exercise to Improve Cardiovascular Health in Early Stage Breast Cancer Survivors (CORE Study)","CORE","Inclusion Criteria:\n\n* History of early-stage breast cancer (I-III)\n* Currently receiving or have completed adjuvant therapy (i.e. chemotherapy, surgery, radiation, targeted therapies)\n* Able to communicate in English\n\nExclusion Criteria:\n\n* Pregnancy\n* Metastatic disease (Stage IV)\n* Unable or unwilling to complete cardiopulmonary exercise test",{"count":528,"type":21},100,"Women with breast cancer who are referred to the cardiac rehabilitation program at the Toronto Rehabilitation Institute will be invited to enrol in this observational study. Participants will take part in an established 16-week multimodal cardiac rehabilitation program (HEALTh program) at Toronto Rehabilitation Institute and outcome measures will be assessed before and after program participation to determine the effectiveness of the program in improving cardio metabolic health. Change in VO₂peak will be assessed using Cardiopulmonary Exercise Test (CPET). Traditional cardiac risk factors, lifestyle behaviours, exercise adherence, health-related quality of life, and fatigue will also be assessed.",[404],[532,533,534,535],"Cardiac Rehabilitation","Cardio-oncology","Cardiometabolic Health","Cardiovascular Disease Risk",{"date":492,"type":39},{"date":538,"type":39},"2022-03-14",{"date":540,"type":21},"2026-12",{"name":45,"class":46},{"id":543,"slug":544,"hasResults":12,"nctId":545,"briefTitle":546,"officialTitle":547,"acronym":548,"eligibilityCriteria":549,"healthyVolunteers":12,"sex":17,"minAge":143,"maxAge":4,"enrollmentInfo":550,"targetDuration":4,"studyType":22,"phases":552,"briefSummary":553,"conditions":554,"keywords":557,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":558,"lastUpdatePostDateStruct":559,"startDateStruct":561,"completionDateStruct":563,"leadSponsor":565,"locationsCount":47},"100564112","behaviour-change-for-cancer-survivors-trial-100564112","NCT06624930","Behaviour Change for Cancer Survivors Trial","A Randomized Controlled Trial Adding Behavioural Counselling to Supervised Physical Activity in Cancer Survivors","BOOST-Up","Inclusion Criteria:\n\n* ≥18 years of age\n* Confirmed diagnosis of cancer of any type (Stages I to III; localized)\n* Have completed primary cancer treatment within 5 years\n* At least 12 weeks after surgery completion\n* At least 6 weeks after radiation treatment\n* Proficient in English\n* Physically inactive (self-report less than 90 min of MVPA\u002Fweek )\n* Ambulate in daily life with minimal gait aid use\n* Access to a smartphone\u002Ftablet\u002Fcomputer with webcam for videoconferencing and a Bluetooth connection\n* Access to the internet\n* No cardiac contraindications (e.g., unstable angina, heart failure, coronary artery disease, diagnosed abnormality of heart rhythm)\n\nExclusion Criteria:\n\n* A medical condition that prohibits PA (e.g., joint restriction or weight bearing precautions)\n* Uncontrolled comorbidities or cardiovascular contraindications that would increase risk associated with supervised and unsupervised exercise (e.g., cardiac contraindications, severe arthritis, recent fall within the last 6-12 months)\n* Presence of advanced cancer (i.e., Stage IV; metastatic)\n* Pregnancy\n* Do not intend to live in Canada for the next 18 months",{"count":551,"type":21},236,[24],"This study will be a two-arm RCT, to examine the effects of an entirely virtual, 6-month supervised PA program plus standard exercise counselling (PA+EC) versus a supervised PA plus motivationally-enhanced behavioral counselling (PA+BC) on moderate to vigorous physical activity (MVPA) in cancer survivors. A 6-month post intervention follow-up (T2) and 1-year post intervention follow-up (T3; 1-year follow-up from post-intervention) will take place after the intervention to address maintenance. The intervention is designed using evidence-based research in the fields of exercise oncology using effective clinical design and theoretical approaches, including behaviour change techniques, to gradually increase MVPA to at least 90 minutes per week in cancer survivors as per the exercise guidelines for cancer survivors.",[555,556],"Cancer","Exercise",[555,556],"2025-09-23",{"date":560,"type":39},"2025-09-29",{"date":562,"type":39},"2024-10-03",{"date":564,"type":21},"2029-05-31",{"name":45,"class":46},{"id":567,"slug":568,"hasResults":12,"nctId":569,"briefTitle":570,"officialTitle":571,"acronym":4,"eligibilityCriteria":572,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":573,"targetDuration":4,"studyType":22,"phases":575,"briefSummary":576,"conditions":577,"keywords":579,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":586,"startDateStruct":588,"completionDateStruct":589,"leadSponsor":591,"locationsCount":47},"100607107","animated-video-education-for-retinal-surgery-100607107","NCT07184255","Animated Video Education for Retinal Surgery","Multilingual Animated Video Education for Retinal Detachment Surgery: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults ≥18 years.\n* Diagnosis of primary rhegmatogenous retinal detachment.\n* Planned repair with pneumatic retinopexy (PnR), pars plana vitrectomy (PPV), or scleral buckle (SB).\n* Able to provide informed consent.\n* Preferred language available among study videos.\n\nExclusion Criteria:\n\n* Repeat retinal detachment surgery in study eye.\n* Combined complex procedures (e.g., PPV + corneal transplant).\n* Severe cognitive impairment precluding consent.\n* Hearing impairment preventing use of audio track (without aid).",{"count":574,"type":21},600,[24],"Retinal detachment is a vision-threatening condition that requires urgent surgical repair. Understanding the condition, the surgery, and post-operative instructions is difficult for many patients, particularly in multilingual and multicultural populations. This study will evaluate whether short, animated educational videos, available in 25 languages and designed with accessibility features for patients with low vision, improve patient knowledge, reduce anxiety, and support adherence to post-operative instructions when added to standard counselling. Patients will be randomized to standard counselling alone versus counselling plus video in their preferred language. Outcomes will be measured with validated questionnaires at baseline, immediately after counselling, and one week post-surgery.",[578],"Retinal Detachment",[578,580,581,582,583,584],"Patient Education","Multilingual Video Intervention","Health Literacy","Eye surgery","Knowledge translation","2025-09-13",{"date":587,"type":39},"2025-09-19",{"date":440,"type":21},{"date":590,"type":21},"2026-12-31",{"name":45,"class":46},{"id":593,"slug":594,"hasResults":12,"nctId":595,"briefTitle":596,"officialTitle":596,"acronym":597,"eligibilityCriteria":598,"healthyVolunteers":12,"sex":205,"minAge":599,"maxAge":4,"enrollmentInfo":600,"targetDuration":4,"studyType":22,"phases":602,"briefSummary":603,"conditions":604,"keywords":605,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":607,"lastUpdatePostDateStruct":608,"startDateStruct":610,"completionDateStruct":612,"leadSponsor":614,"locationsCount":47},"100542674","multiple-risk-factor-intervention-trial-ms-fit-100542674","NCT06345937","Multiple Risk Factor Intervention Trial (Ms. FIT)","MsFIT","Inclusion Criteria:\n\n* Biologically female\n* Aged 30+\n* Pre- or postmenopausal: Premenopause: having regular menstrual cycles (21-35 days long without a persistent difference of ≥7 days between cycles). Post-menopause: ≥12 months of amenorrhea or history of double oophorectomy and do not have irregular or occasional menstrual cycle in last 12 months.\n* Participants will have multiple risk factors for cardiometabolic disease, namely: being sedentary (\\\u003C30 min of moderate-vigorous physical activity\u002Fweek), having a BMI ≥ 25 kg\u002Fm\\^2, and one or more of the following: a waist circumference indicative of abdominal obesity, specific to BMI (e.g., BMI 25-29.9: WC: ≥90cm; BMI 30-34.9: WC: ≥105cm; BMI 35-35.9: WC: ≥115cm) OR a diagnosis of either hypertension, pre-diabetes (heightened blood sugar levels), or dyslipidemia (heightened blood lipid levels)\n* Able to commit to come to the University once per week for 24 weeks.\n\nExclusion Criteria:\n\n* Perimenopausal or those whom the investigators cannot discern pre- vs perimenopausal status\n* Diagnosed cardiovascular diseases, type 2 diabetes, non-alcoholic fatty liver disease, cancer (except for non-melanoma skin cancer), or respiratory disease (e.g., Chronic obstructive pulmonary disease (COPD) or severe or uncontrolled asthma).\n* Major signs or symptoms of cardiovascular diseases, diabetes, or renal disease (taken from the American College of Sports Medicine's Guidelines for Exercise Testing and Prescription 11th edition Table 2.1: pain or discomfort in the chest, neck, jaw, arms with rest or exercise, shortness of breath at rest or with mild exertion, dizziness or syncope, loss of balance or passing out, ankle edema, palpitations or tachycardia, intermittent claudication, known heart murmur, unusual fatigue with usual activities.)\n* American Heart Association's absolute or relative contraindications for symptom-limited maximal exercise testing (myocardial infarction, aortic or coronary artery stenosis, heart failure, pulmonary embolism or deep vein thrombosis, inflammation of the heart (myocarditis, pericarditis, and\u002For endocarditis), uncontrolled cardiac arrythmia, advanced or complete electrical heart block, stroke or transient ischemia attack, blood pressure \\>200mmHg\u002F100mmHg, a cancer diagnosis other than skin cancer)\n* Unable to provide informed consent or communicate in English\n* Pregnant or breast-feeding currently or in the past 3 months\n* Mobility limitations to aerobic exercise (i.e., wheelchair, walker use, limp impeding walking)\n* Smoking cigarettes or marijuana within the past 3 months\n* Taking exogenous hormones in any format currently or in the past 3 months\n* Contraindications to research MRI (e.g., pacemaker, magnetic implants)\n* BMI exceeding 40 kg\u002Fm2\n* Extreme claustrophobia\n* Self-report \\>30 min\u002Fweek of moderate-to-vigorous intensity aerobic physical activity\n* Following a diet that largely restricts entire food groups or time of eating (e.g., vegan, ketogenic, carnivore, one meal a day) in last 3 months\n* Students in classes or labs of the professors who are involved in the study\n* Experienced significant weight loss (i.e., \\>5 kg) in past 3 months\n* Currently taking weight loss medications\n* Diagnosed history of an eating disorder or self-report of potential undiagnosed eating disorder\n* Plans to be away\u002Funavailable for a substantial period of the intervention overall (i.e., \\>4 weeks throughout the 6 months or \\>2 weeks within the first 12 weeks of the intervention).\n* Allergies to local anesthetics","30 Years",{"count":601,"type":21},180,[24],"This study aims to produce new evidence, specific to women, on the efficacy and mechanisms of exercise and diet for cardiometabolic risk reduction in pre and postmenopausal women. Using a 3-arm randomized controlled trial (RCT) with equal recruitment and stratification by menopausal status to 6 months of: 1) exercise following Health Canada guidelines; 2) the same exercise plus counselling to follow Canada's Dietary Guidelines to improve diet quality; or 3) stretching group, this study will answer the following questions:\n\n* How does the impact of exercise compare among each of the causal links between physical inactivity and cardiometabolic disease in women?\n* What is the effect modification of adding a diet quality intervention to exercise?\n* What is the effect modification by menopausal status?\n\nThe investigators hypothesize that exercise adaptations will be: 1) largest peripherally, including Matsuda index (primary outcome), Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), arteriovenous oxygen difference (avO2diff), and visceral fat, compared to centrally (stroke volume (SV), endothelial function, aortic stiffness), 2) blunted or absent in post vs premenopause; 3) enhanced by the addition of diet quality which will be essential or additive for Matsuda index, metabolic syndrome, Framingham cardiovascular disease (CVD) risk, cytokines and adipokines, thigh myosteatosis, muscle mass, peak oxygen uptake (VO2peak), 4) enhanced by adding diet quality in more outcomes postmenopause.",[510,511],[606],"Primary Prevention","2025-09-11",{"date":609,"type":39},"2025-09-17",{"date":611,"type":39},"2024-05-03",{"date":613,"type":21},"2028-08-01",{"name":45,"class":46},{"id":616,"slug":617,"hasResults":12,"nctId":618,"briefTitle":619,"officialTitle":620,"acronym":621,"eligibilityCriteria":622,"healthyVolunteers":12,"sex":205,"minAge":18,"maxAge":4,"enrollmentInfo":623,"targetDuration":4,"studyType":22,"phases":625,"briefSummary":626,"conditions":627,"keywords":629,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":632,"lastUpdatePostDateStruct":633,"startDateStruct":635,"completionDateStruct":637,"leadSponsor":638,"locationsCount":47},"100603120","feasibility-of-different-types-of-exercise-training-in-perimenopausal-females-100603120","NCT07132385","Feasibility of Different Types of Exercise Training in Perimenopausal Females","Perimenopause: Window for Exercise and Resilience Pilot Study","POWER","Inclusion Criteria:\n\n* Biological females in early and late perimenopause. Menopausal stage will be defined according to the Stages of Reproductive Aging Workshop +10 (STRAW+10). According to STRAW+10, perimenopause is characterized by menstrual cycle irregularity, specifically defined as having bleeding in the previous 12 months but at least a 7-day difference from usual menstrual cycle length\n* Experiencing menopause symptoms (e.g., hot flashes, night sweats, joint stiffness)\n* Aged 40 years or older\n* Multiple risk factors for cardiometabolic disease, namely being sedentary (\\\u003C30 min of moderate-vigorous physical activity\u002Fweek), having a BMI ≥25 kg\u002Fm2, and a waist circumference indicative of abdominal obesity, specific to BMI (e.g., BMI 25-29.9: WC: 90cm; BMI 30-34.9: WC: 105cm; BMI 35-35.9: WC:115cm).\n\nExclusion Criteria:\n\n* History of reproductive surgeries including oophorectomy, hysterectomy, ablation or gender-affirming.\n* Diagnosis of cardiovascular disease, type 2 diabetes, non-alcoholic fatty liver disease, cancer (except for non-melanoma skin cancer), respiratory disease (e.g., Chronic Obstructive Pulmonary Disease or severe or uncontrolled asthma), uncontrolled hyper- or hypogonadism (change in medication or dosage in last 6 months and with major symptoms), and\u002For Polycystic Ovary Syndrome\n* Major signs or symptoms (regardless of known diagnosis) of cardiovascular diseases, diabetes, or renal disease\n* The use of medication that could impact blood glucose\n* Pregnant or post-partum \\\u003C12 months, lactating or breast feeding within 3 months of the start of study\n* Recreational smoking (e.g., tobacco, smoking)\n* Actively engaging in a low-carbohydrate diet (e.g., ketogenic, Atkins)\n* Using transdermal hormones, taking exogenous hormones, or receiving exogenous hormones from other means (e.g., intrauterine device)\n* Significant weight loss (i.e., \\>5 kg) in past 3 months or currently taking weight loss medications",{"count":624,"type":21},30,[24],"Throughout the menopause transition, women experience many symptoms (i.e., hot flashes, night sweats) that can significantly reduce their quality of life. Moreover, their risk of heart disease increases substantially. The years before menopause called \"perimenopause\" present a critical window of intervention to alleviate menopause symptoms and improve health outcomes. Our team is therefore interested in comparing the potential benefits of different approaches including following the Health Canada guidelines (i.e., accumulating 150 min of moderate-to-vigorous aerobic physical activity weekly); performing high-intensity interval training (HIIT), which involves alternating periods of intense exercise with periods of rest; or stretching in perimenopause. As a first step towards this goal, this study will assess how easy and enjoyable the interventions are to follow over a 6-week period. The information gained from this study will be used to perform a larger study with enough participants to assess the health and quality of life impacts of adopting these different strategies in perimenopause.",[628],"Women",[630,631,214],"menopause","perimenopause","2025-09-02",{"date":634,"type":39},"2025-09-09",{"date":636,"type":39},"2025-09-01",{"date":38,"type":21},{"name":45,"class":46},{"id":640,"slug":641,"hasResults":12,"nctId":642,"briefTitle":643,"officialTitle":643,"acronym":644,"eligibilityCriteria":645,"healthyVolunteers":12,"sex":17,"minAge":143,"maxAge":4,"enrollmentInfo":646,"targetDuration":4,"studyType":22,"phases":648,"briefSummary":649,"conditions":650,"keywords":652,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":658,"lastUpdatePostDateStruct":659,"startDateStruct":661,"completionDateStruct":663,"leadSponsor":664,"locationsCount":106},"100568183","sciu-peer-health-coaching-program-for-individuals-newly-discharged-from-inpatient-rehabilitation-100568183","NCT06677905","SCI&U Peer Health Coaching Program for Individuals Newly Discharged From Inpatient Rehabilitation","SCIU2","Inclusion Criteria:\n\n* 18 years and older, with a planned discharge to or living in community with SCI for no more than three years since injury and with the ability to speak and understand English\n\nExclusion Criteria:\n\n* not a member of or willing to become a member of SCI BC or SCIACT",{"count":647,"type":21},76,[24],"The goal of this clinical trial is to learn if the online program and web-based platform for delivery of self-management services to people with spinal cord injury (SCI) called \"SCI \\& U\" can support transitions from hospital to the community after injury. Specifically, can providing support from trained peer health coaches via the SCI \\& U web-based self-management program increase health self-management among those within three years of a spinal cord injury with a planned discharge to or living in the community with SCI for less than two years in the province of British Columbia, Canada or the state of Connecticut, United States.\n\nThe main question it aims to answer is:\n\n• Does the SCI \\& U web-based self-management program lower emotional distress and increase self-efficacy Researchers will compare those who participate in SCI \\& U with those who receive usual peer support after 6 months to see if the SCI \\& U program improves self-management knowledge, skills and self-efficacy and decreases secondary complications\n\nParticipants will:\n\n* engage in up to 14 online sessions, each of which lasts about an hour with a peer health coach trained in motivational interviewing, goal setting and brief action planning. During sessions, they may also review resources and create follow up plans on the online platform on health management topics\n* complete an interviewer administered survey at baseline, 6 and 12 months",[651],"Spinal Cord Injury",[653,654,655,656,657],"peer support","self-management","spinal cord injury","newly injured","web-based program","2025-08-28",{"date":660,"type":39},"2025-09-05",{"date":662,"type":39},"2025-02-21",{"date":590,"type":21},{"name":45,"class":46},{"id":666,"slug":667,"hasResults":12,"nctId":668,"briefTitle":669,"officialTitle":670,"acronym":671,"eligibilityCriteria":672,"healthyVolunteers":12,"sex":17,"minAge":143,"maxAge":673,"enrollmentInfo":674,"targetDuration":4,"studyType":22,"phases":676,"briefSummary":677,"conditions":678,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":681,"lastUpdatePostDateStruct":682,"startDateStruct":684,"completionDateStruct":686,"leadSponsor":688,"locationsCount":106},"100495455","outcomes-from-remediation-and-behavioural-intervention-techniques-100495455","NCT05731414","Outcomes From Remediation and Behavioural Intervention Techniques","Cognitive Behavioural Therapy Compared to Cognitive Remediation for Schizophrenia-Spectrum Disorders","ORBIT","Inclusion Criteria:\n\n* Aged 18-65 years\n* Diagnosed with schizophrenia-spectrum disorders\n* Can read, write, and speak English\n\nExclusion Criteria:\n\n* Neurodevelopmental disability or neurocognitive disorder\n* CBT or CR in the past 6 months","65 Years",{"count":675,"type":21},360,[24],"It is currently unknown what factors predict response to Cognitive Behavioural Therapy for Psychosis (CBTp) or Cognitive Remediation Therapy (CR) among individuals with schizophrenia-spectrum disorders, thus the current trial will examine predictors of response to determine who requires the combined intervention and who might respond sufficiently to either monotherapy.",[156,151,679,680],"Psychotic Disorders","Schizophrenia; Psychosis","2025-08-13",{"date":683,"type":39},"2025-08-19",{"date":685,"type":39},"2023-03-01",{"date":687,"type":21},"2027-01-31",{"name":45,"class":46},""]